There were 1,065 press releases posted in the last 24 hours and 430,340 in the last 365 days.

AngioSoma Explores New Cosmoceutical Products

Research and Development Focus on Natural Skin Products for Women and Men

HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today the exploration of new and improved versions of current products and a new line of facial products designed for men. 

AngioSoma currently markets three beauty products with a focus on maintaining a youthful appearance.  Its Collagen Anti-Aging Crème is a powerful skin nourishing formulation that rejuvenates the skin by acting right into the deeper skin-layers, with its natural ingredients acting upon each cell within.   The Powerful Peptide Eye Serum stops the sign of aging around the eyes giving a visibly younger look and feel.  And its Anti-Wrinkle Serum is a premium “All Natural” product loved by thousands for its unique rapid action skin-smoothing effect. 

“We hope to build on the success of our current products and make them more effective,” said Alex Blankenship, President. “Plus, the addition of a men’s line of facial products will make us more competitive in the marketplace and provide diversity in our portfolio as a company.”

You can view and purchase products on Amazon.com:  Go to Amazon Now

Also, products can be found on our ecommerce site: YouthfulBrilliance.com.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (https://angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Contacts

AngioSoma, Inc.
Alex Blankenship
investors@AngioSoma.com

5b2d4661dbf98c0004b12098_1.png

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.